ESMO Asia 2025 Oral Presentation: Ficerafusp alfa 750 mg QW and pembrolizumab in HPV-negative first line recurrent/metastatic head and neck squamous cell carcinoma

Bicara Therapeutics Inc. published this content on December 06, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on December 06, 2025 at 13:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]